

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:	DALLY Robert Dean	Group Art Unit:	1624
Serial No.:	10/599,129	Examiner:	Douglas M. WILLIS
Application Date:	April 8, 2005	Conf No.:	4638
US Nat'l Entry			
Date (if applicable): September 20, 2006			
For:	PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS		
Docket No.:	X-17115		

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the following comments on the Statement of Reasons for Allowance be entered in the file for the application identified above. Applicants do not believe that any fees are incurred; however, any fees associated with this paper may be charged to Eli Lilly Deposit Account No. 05-0840.

Applicants agree with Examiner concerning Reasons for Allowance: "The prior art is silent with regard to pyrrolidines substituted with R¹, as recited in Claim 2. Consequently, the limitation on the core of the substituted pyrrolidines of the formula I(a) that is not taught or fairly suggested in the prior art is R¹ on the periphery of the pyrrolidine core." Allowance Notice, dated June 03, 2009, page 5. Previously in a telephone interview on May 14, 2009, Applicants acknowledged their continuing duty to the United States Patent and Trademark Office wherein upon allowance of the claims in the present application to provide a copy of the claims to the Examiner in the co-pending application, 10/599,125, and to fully address the outstanding issues in that case, as necessary.

Respectfully submitted,

/Elizabeth A. Dingess-Hammond/

Elizabeth A. Dingess-Hammond
Agent for Applicants
Registration No. 63,996
Phone: 317-433-3689

Eli Lilly and Company
Patent Division/
P.O. Box 6288
Indianapolis, Indiana 46206-6288

July 31, 2009
